Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMLM28 ADAPT Domain 1: navitoclax added to venetoclax + azacitidine for AML with TP53 aberrations or persistent MRD
ACTRN12623000851662Phase 2Withdrawn
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Feb 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of navitoclax, venetoclax and azacitidine in acute myeloid leukemia (AML) (2 arms), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoints: Recommended phase 2 dose determination, Overall survival in TP53 stratum and 1 more. Planned start Feb 2024; status: withdrawn.
02
Drugs
navitoclaxvenetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12623000851662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000851662.